Advertisement
Over the past decade, Abbott has reshaped its business portfolio with afocus on high-growth, innovation-driven businesses with market-leadingpotential.The company:
Advertisement
-- Acquired Knoll Pharmaceuticals, positioning Abbott as a global leaderin biotechnology with HUMIRA(R), a biologic for treating several debilitatingautoimmune diseases. Since its launch in 2003, HUMIRA has grown to more than$3 billion in annual sales in 2007 and Abbott expects sales of more than $4.4billion in 2008.
-- Purchased Kos Pharmaceuticals (http://tinyurl.com/5t4tc4), immediatelyenhancing Abbott's existing franchise and portfolio strength in the $20billion lipid management market.
-- Acquired Guidant's vascular business, (http://tinyurl.com/5jhjym)providing Abbott with the innovative drug-eluting stent, XIENCE V(TM)(http://tinyurl.com/5cwfns), and the world's first bioabsorbable drug-elutingstent (http://tinyurl.com/6pahst) to enter clinical trials. With nearlyglobal availability since July 2008, XIENCE V has quickly gained marketleadership based on strong clinical data.
-- Entered high-growth vascular and point-of-care markets through theacquisitions of Perclose and i-STAT and enhanced its leadership position indiabetes care with the purchase of TheraSense.
"Abbott has taken a deliberate approach to acquisitions, identifying andpursuing transactions that either complement our existing portfolio or allowus to enter new innovation-driven markets with leadership potential," saidMiles D. White (http://tinyurl.com/5fa29a), chairman and chief executiveofficer, Abbott. "This strategic approach, combined with our internal R&Defforts, has enabled Abbott to consistently deliver industry-leadingperformance and generate double-digit returns for our shareholders."
The Deal's readers rated Abbott best on all four of its award criteria:choice of targets and strategy; price paid (or received) compared to value;execution, including integration; and overall quality of the deal team.Companies considered for the survey have a market capitalization of $5 billionor more as of June 30, 2008, and closed the highest number and dollar value ofacquisitions and divestitures in the past three years.
About Abbott
Abbott (NYSE: ABT) is a global, broad-based health care company devoted tothe discovery, development, manufacture and marketing of pharmaceuticals andmedical products, including nutritionals, devices and diagnostics. Thecompany employs more than 68,000 people and markets its products in more than130 countries.
About The Deal LLC
The Deal LLC, (http://www.thedeal.com), is a diversified media companythat is the authoritative voice of the deal economy. The Deal LLC serves theglobal deal community -- corporate and financial dealmakers, advisers andinstitutional investors -- by providing business and financial news andinformation that offers fresh insights on the deal economy, a set ofinterrelated activities, focused on dealmaking of all kinds, whose purpose isto generate corporate growth in a continually changing global market. TheDeal LLC offers a comprehensive line of print and electronic products -- TheDeal, The Daily Deal and TheDeal.com -- and live annual events includingPrivate Capital Symposium, Distressed Investing Forum, Corporate DealmakerForum and M&A Outlook. The Deal LLC, a privately held company, is owned byprivate investment funds, including U.S. Equity Partners LP, sponsored byWasserstein & Co. LP.
SOURCE Abbott
